AI Stock Analysis - Merck & Company (MRK)
Analysis generated February 4, 2026.
Merck Company, a global healthcare leader, is dedicated to improving health and well-being around the world. As a major pharmaceutical firm, Merck develops, manufactures, and markets products that are mainly for therapeutic and preventive treatment. The company's extensive portfolio includes prescription medicines, vaccines, biologic therapies, and animal health products, making it a pivotal player in the healthcare sector.
Stock Alerts - Merck & Company (MRK)
 |
Merck & Company | March 12 AI Score is up by 33.2% in the last couple of days. |
|
Merck & Company | February 12 Michael McCaul (member of U.S. congress) is selling shares |
|
Merck & Company | February 11 Insider Alert: Li Dean Y is selling shares |
|
Merck & Company | February 10 Insider Alert: Zachary Jennifer is selling shares |
Download our app to get future alerts delivered in real-time.
Alternative Data for Merck & Company
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 234 | Sign up | Sign up | Sign up |
| Sentiment | 84 | Sign up | Sign up | Sign up |
| Webpage traffic | 720,000 | Sign up | Sign up | Sign up |
| Employee Rating | 82 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 46 | Sign up | Sign up | Sign up |
| Facebook Followers | 96,572 | Sign up | Sign up | Sign up |
| Instagram Followers | N/A | Sign up | Sign up | Sign up |
| Reddit Mentions | 1 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 49 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 25,739 | Sign up | Sign up | Sign up |
| X Followers | 216,439 | Sign up | Sign up | Sign up |
| X Mentions | 56 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 3,970 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 70 | Sign up | Sign up | Sign up |
| Linkedin Employees | 44,772 | Sign up | Sign up | Sign up |
| NPS | 35 | Sign up | Sign up | Sign up |
About Merck & Company
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products.
| Price | $115.61 |
| Target Price | Sign up |
| Volume | 8,321,571 |
| Market Cap | $287B |
| Year Range | $76.7 - $123.93 |
| Dividend Yield | 2.79% |
| PE Ratio | 15.94 |
| Analyst Rating | 59% buy |
| Earnings Date | April 30 '26 |
| Industry | Drug Manufacturers |
In the news
RBC Capital Initiates Coverage of Merck (MRK) with Outperform RecommendationFebruary 24 - Fintel |
|
 |
Has Merck (MRK) Run Too Far After Its 41% Discount To Estimated Fair Value?February 24 - Yahoo |
|
Merck (MRK) Announces Positive Phase 3 SMART Trial Results for ENFLONSIA (Clesrovimab)February 23 - Yahoo |
|
Barclays Highlights Merck’s (MRK) Pipeline Catalysts in Coverage InitiationFebruary 23 - Yahoo |
CNBC Halftime Report Final Trades: Amazon, Merck & Company, Pacific Gas & Electric Co., Horizon Kinetics Inflation Beneficiaries ETFFebruary 22 - Benzinga |
|
|
Deutsche Bank Upgrades Merck (MRK) to Buy, Sees “Clear Path” Beyond Keytruda Patent CliffFebruary 20 - Yahoo |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q4 '25 | 16.4B | 1.2B | 15.2B | 2.96B | 6.83B | 2.040 |
| Q3 '25 | 17.3B | 3.86B | 13.4B | 5.79B | 8.23B | 2.580 |
| Q2 '25 | 15.8B | 3.56B | 12.2B | 4.43B | 6.42B | 2.130 |
| Q1 '25 | 15.5B | 3.42B | 12.1B | 5.08B | 7.32B | 2.220 |
| Q4 '24 | 15.6B | 3.83B | 11.8B | 3.74B | 5.7B | 1.720 |
Insider Transactions View All
| Guindo Chirfi filed to sell 60,615 shares at $121.5. February 12 '26 |
| Li Dean Y filed to sell 92,035 shares at $117.5. February 10 '26 |
| Zachary Jennifer filed to sell 68,916 shares at $119.2. February 9 '26 |
| Zachary Jennifer filed to sell 68,916 shares at $119.2. February 9 '26 |
| Zachary Jennifer filed to sell 68,916 shares at $119.2. February 9 '26 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$241.52 0.2% | 56 |
 |
Eli Lilly and CompanyLLY |
$985.08 0.8% | 61 |
 |
PfizerPFE |
$26.58 1% | 28 |
 |
AstrazenecaAZN |
$189.9 1.4% | 50 |
 |
AbbVieABBV |
$219.68 2.5% | 61 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Michael McCaul |
Feb 12, 26 | Sell | $15K - $50K |
| Julie Johnson |
Jan 16, 26 | Sell | $1K - $15K |
| Gilbert Cisneros |
Jan 13, 26 | Buy | $1K - $15K |
Read more about Merck & Company (MRK) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Merck & Company
The Market Cap of Merck & Company is $287B.
As of today, Merck & Company's PE (Price to Earnings) ratio is 15.94.
Merck & Company will report its next earnings on April 30 '26.
Currently, the price of one share of Merck & Company stock is $115.61.
The MRK stock price chart above provides a comprehensive visual representation of Merck & Company's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Merck & Company shares. Our platform offers an up-to-date MRK stock price chart, along with technical data analysis and alternative data insights.
Yes, Merck & Company (MRK) offers dividends to its shareholders, with a dividend yield of 2.79%. This dividend yield represents Merck & Company's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Merck & Company in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
Some of the similar stocks of Merck & Company are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
